Randomized trial reveals adverse cardiovascular outcomes in Black patients treated with clopidogrel, highlighting racial disparities.
Cytochrome P450 2C19 (CYP2C19) intermediate and poor metabolizer patients exhibit diminished clopidogrel clinical effectiveness after percutaneous coronary intervention (PCI). However, outcome studies to date have lacked racial diversity. Thus, the impact of
No takes yet. Share an insight, caveat, or question.
Tunehag et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: